While eRegulatory (eInvestigator Site File) systems favored by study sponsors offer many advantages to sites, their adoption and use may place burdens on site personnel that can be alleviated with careful planning and collaboration between partners. Speakers in this session will share specific use cases where the use of eRegulatory has made a positive impact on clinical trials, as well as overall metrics on site adoption, user feedback from site and sponsor roles, lessons learned and future opportunities for both study coordinators and monitors.

Speakers

• Dan Knight, Associate Director of Clinical Research at Merck
• Kayla Perry, Clinical Research Associate at Merck

Event Agenda
5:00 – 5:15 pm – Registration and sign-in
5:15 – 6:00 pm – Presentation
6:00 – 6:30 pm – Q&A and Networking

Learning Objectives

• Understand reasons why a site might or might not want to adopt an eRegulatory system
• Understand the benefits and challenges for sites and sponsors in adoption
• Hear best practices related to set-up, integration, monitoring and change management in the adoption of an eRegulatory and source-sharing solution

Register + Learn More